Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 8/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495662 | 0.87 | AKR1C3 (0.55) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495355 | 0.87 | AKR1C3 (0.44) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495494 | 0.84 | AKR1C3 (0.45) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495354 | 0.84 | AKR1C3 (0.45) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495395 | 0.84 | AKR1C3 (0.44) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495403 | 0.84 | AKR1C3 (0.44) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL12757533 | 0.83 | MEN1 (0.46) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495539 | 0.82 | AKR1C3 (0.54) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495364 | 0.82 | AKR1C3 (0.44) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 | |
| SCHEMBL1495362 | 0.82 | P2RX3 (0.45) | AKR1C3AKR1C4AKR1C2AKR1C1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| CN-104058999-A | Amide Compounds, Compositions And Uses Thereof | RENOVIS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-104016907-A | Amide compounds, compositions and uses thereof | RENOVIS INC | 2014-09-03 | — | — | CN | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | AKR1C3 973/4885AKR1C4 1109/4885AKR1C2 1626/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | AKR1C3 973/4885AKR1C4 1109/4885AKR1C2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.